序号股票简称PE(TTM)PE(静)市净率总市值(元)18辰光医疗-26.35-26.157.2515.92亿行业平均 49.8445.684.61105.51亿行业中值36.5938.052.4346.93亿1天益医疗-1742.06-2983.951.8622.20亿2澳华内 镜-602.36302.124.8363.48亿3诺唯赞-409.62-484.482.2587.66亿4爱朋医疗-362.84275.654.3729.77亿5博晖 创新-324.04514.213.4647.54亿6硕世生物-131.86-1926.851.1838.57亿7奥精医疗-125.28-183.621.6523.25亿 8睿昂基因-99.99-82.091.4212.94亿9康泰医学-84.67-71.543.0255.73亿10中红医疗-70.88-56.530.9049.26亿 11华大智造-59.73-53.004.11318.43亿 来源：金融界 资金流向方面，5月12日，辰光医疗主力资金净流入83.44万元，近5日总体呈流入状态，5日共流入 718.75万元。 上海辰光医疗科技股份有限公司主营业务是超导MR ...

Group 1 - The core business of the company is the research, production, and sales of superconducting MRI systems and specialized magnets in high-tech fields [1] - The company has a market capitalization of 1.509 billion yuan and a latest price-to-book ratio of 6.88 [1] - The company reported a revenue of 25.0744 million yuan in Q1 2025, representing a year-on-year increase of 20.21%, while the net profit was -8.5827 million yuan, a year-on-year decrease of 5.22% [1] Group 2 - The company has received several recognitions, including being named a "Technology Little Giant" enterprise in Shanghai and a national-level "Specialized and New" small giant enterprise [1] - The company’s sales gross margin stands at 30.84% [1] - The company experienced a net inflow of 8.4283 million yuan in main funds on May 6, with a total inflow of 15.8293 million yuan over the past five days [1]

Group 1 - The core business of the company is the research, production, and sales of superconducting MRI systems and special magnets in high-tech fields [1] - The company has received several recognitions, including being named a "Technology Little Giant" enterprise in Shanghai and a national-level "Specialized and Innovative" small giant enterprise [1] - The latest financial results show a revenue of 86.11 million yuan for the third quarter of 2024, representing a year-on-year decrease of 13.44%, with a net loss of approximately 15.88 million yuan, a year-on-year decline of 129.77% [1] Group 2 - The company's current price-to-earnings (P/E) ratio is -25.68, with a price-to-book (P/B) ratio of 5.45 and a total market capitalization of 1.489 billion yuan [2] - The industry average P/E ratio is 48.08, while the industry median is 30.21, indicating that the company is significantly below industry benchmarks [2] - The company has experienced a net outflow of 15.09 million yuan in principal funds on April 22, with a total outflow of 40.22 million yuan over the past five days [1]

Company Overview - Chuangguang Medical closed at 17.28 yuan, down 9.15%, with a latest price-to-book ratio of 5.43 and a total market capitalization of 1.483 billion yuan [1] - The company specializes in the research, production, and sales of superconducting MRI systems and special magnets in high-tech fields [1] - Chuangguang Medical has been recognized as a high-tech enterprise, receiving titles such as "Technology Small Giant Enterprise" and "Specialized and Innovative Small Giant Enterprise" at both municipal and national levels [1] Financial Performance - For the third quarter of 2024, the company reported operating revenue of 86.1063 million yuan, a year-on-year decrease of 13.44% [1] - The net profit for the same period was -15,875,336.84 yuan, reflecting a year-on-year decline of 129.77% [1] - The sales gross margin stood at 41.27% [1] Market Sentiment - On March 26, the net outflow of main funds for Chuangguang Medical was 38.8682 million yuan, indicating a trend of outflow over the past five days, totaling 45.3674 million yuan [1] Industry Comparison - The average price-to-earnings (PE) ratio for the industry is 45.14, while Chuangguang Medical's PE (TTM) is -25.58 [2] - The industry median PE is 31.99, and the average price-to-book ratio is 4.84, compared to Chuangguang Medical's 5.43 [2]